CRL
Charles River LaboratoriesNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$8.23B
P/E Ratio
—
EPS
$-2.90
Beta
1.62
52W High
$228.88
52W Low
$113.89
50-Day MA
$169.23
200-Day MA
$175.81
Dividend Yield
—
Profit Margin
-3.60%
Forward P/E
15.41
PEG Ratio
0.12
About Charles River Laboratories
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Fundamentals
| Revenue (TTM) | $4.02B |
| Gross Profit (TTM) | $1.40B |
| EBITDA | $876.57M |
| Operating Margin | 4.51% |
| Return on Equity | -4.23% |
| Return on Assets | 4.24% |
| Revenue/Share (TTM) | $81.01 |
| Book Value | $64.30 |
| Price-to-Book | 2.67 |
| Price-to-Sales (TTM) | 2.05 |
| EV/Revenue | 2.691 |
| EV/EBITDA | 26.30 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | -0.80% |
| Shares Outstanding | $49.34M |
| Float | $48.66M |
| % Insiders | 0.85% |
| % Institutions | 109.52% |
Historical Volatility
HV 10-Day
57.72%
HV 20-Day
45.25%
HV 30-Day
47.97%
HV 60-Day
55.66%
HV Rank
57.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($199.33 target)
1
Strong Buy10
Buy6
HoldData last updated: 4/29/2026